Business

Aelis Farma Announces Its 2026 Financial Calendar

BORDEAUX, France, January 26, 2026--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces its indicative financial calendar for the financial year 2026.

articleAelis Farma SaJanuary 26, 20264/company/aelis-farma-sa-1/news/aelis-farma-announces-its-2026-financial-calendar-1
Aelis Farma Announces Its 2026 Financial Calendar

About this update from Aelis Farma Sa

[{"type":"text","content":"BORDEAUX, France, January 26, 2026--(BUSINESS WIRE)--Regulatory News:","length":69,"tagName":"p"},{"type":"text","content":"Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces its indicative financial calendar for the financial year 2026.","length":297,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"1","rowspan":"1","style":"border-top:solid black 1.0pt;border-bottom:solid black 1.0pt;border-left:solid black 1.0pt;border-right:solid black 1.0pt;background-color:#CCEEFF;padding-left:0.0px;width:60%;","val":[{"type":"text","content":" Event","length":5,"tagName":"p","attribs":{}}]},{"colspan":"1","rowspan":"1","style":"border-top:solid black 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;background-color:#CCEEFF;padding-left:0.0px;width:40%;","val":[{"type":"text","content":" Date of release*","length":16,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan":"1","rowspan":"1","style":"border-bottom:solid black 1.0pt;border-left:solid black 1.0pt;border-right:solid black 1.0pt;padding-left:0.0px;width:60%;","val":[{"type":"text","content":"2025 Annual Results","length":19,"tagName":"p","attribs":{}}]},{"colspan":"1","rowspan":"1","style":"border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding-left:0.0px;width:40%;","val":[{"type":"text","content":"Monday, March 30, 2026","length":22,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan":"1","rowspan":"1","style":"border-bottom:solid black 1.0pt;border-left:solid black 1.0pt;border-right:solid black 1.0pt;padding-left:0.0px;width:60%;","val":[{"type":"text","content":"Annual General Meeting","length":22,"tagName":"p","attribs":{}}]},{"colspan":"1","rowspan":"1","style":"border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding-left:0.0px;width:40%;","val":[{"type":"text","content":"Wednesday, June 3, 2026","length":23,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan":"1","rowspan":"1","style":"border-bottom:solid black 1.0pt;border-left:solid black 1.0pt;border-right:solid black 1.0pt;padding-left:0.0px;width:60%;","val":[{"type":"text","content":"2026 Half-Year Results","length":22,"tagName":"p","attribs":{}}]},{"colspan":"1","ro...

More updates from Aelis Farma Sa

Aelis FarmaCB1 receptorbiopharmaceutical companyDr Pier Vincenzo PiazzaForward-looking statements